Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

-  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE^TM programs anticipated in 2024 -

-  WTX-124: updated interim monotherapy dose-escalation data and initial combination dose escalation data from Phase 1/1b clinical trial expected in 1H 2024 -

-  WTX-330: preliminary dose-escalation data from Phase 1 clinical trial expected in 2Q 2024 -

-  Updated cash guidance provides runway through at least the first quarter of 2025 -

WATERTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and outlined its strategic outlook and expected milestones for 2024.

Werewolf outlined the following objectives as the Company’s strategic priorities for 2024:

1. Prioritize development of wholly owned clinical-stage programs – present data updates from WTX-124 and WTX-330 while advancing their clinical development.
2. Progress preclinical programs through IND-enabling work – demonstrate the breadth of Werewolf’s platform and portfolio opportunities.
3. Apply PREDATOR platform for non-core opportunities and external innovation – leverage Werewolf’s validated technical capabilities, preclinical programs and opportunities in inflammatory diseases.
4. Maintain disciplined spend – prudently allocate resources according to these priorities to optimize cash runway with continued focus on clinical development of lead programs.

“2023 was an important year for Werewolf, highlighted by preliminary monotherapy data from our IL-2 program that offered proof of concept for WTX-124 and for our INDUKINE design more broadly,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “In 2024, we expect to share progress from our wholly owned clinical programs, with updated monotherapy data and initial combination data from WTX-124 as well as our first look at WTX-330. In particular, for WTX-124, we hope to build upon the promising signals of antitumor activity and improved therapeutic index that we observed in the highest dose cohort presented at SITC.”